Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

INTRODUCTION: Despite a clinically relevant, statistically significant survival benefit with nab-paclitaxel plus gemcitabine and FOLFIRINOX vs single-agent gemcitabine for metastatic pancreatic cancer (mPC), little is known regarding their real-world effectiveness. We analyzed patients with mPC usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Braiteh, Fadi, Patel, Manish B, Parisi, Monika, Ni, Quanhong, Park, Siyeon, Faria, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409189/
https://www.ncbi.nlm.nih.gov/pubmed/28461766
http://dx.doi.org/10.2147/CMAR.S126073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409189/
https://www.ncbi.nlm.nih.gov/pubmed/28461766
http://dx.doi.org/10.2147/CMAR.S126073

Ejemplares similares